Baker Bros. Advisors Adds $87M in Insmed Incorporated ($INSM)
Key Points
- Baker Bros. Advisors changed its Insmed Incorporated ($INSM) stake by 12.56% last quarter, boosting to 7,421,111 shares worth $777.29 million.
- Wall Street's consensus rating on $INSM is Strong Buy and an average price target of $200.18.
- $INSM last traded around $104.74.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Baker Bros. Advisors increased its position in Insmed Incorporated ($INSM) by 12.56% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,421,111 shares of Insmed Incorporated after buying 828,365 shares during the quarter. Baker Bros. Advisors's holdings in Insmed Incorporated were worth $777.29 million as of its most recent filing.
Insmed Incorporated Stock Down 11.6%
Shares of Insmed Incorporated ($INSM) traded around $104.74 on Saturday, down 11.6% for the day.
Insmed Incorporated Earnings
Analysts Set New Price Targets
About Insmed Incorporated
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Get Insmed Incorporated alerts
New 13F filings, insider trades, and analyst moves on $INSM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.